Literature DB >> 4479715

Decreased cardiac toxicity of adriamycin and daunorubicin when bound to DNA.

A Langslet, I Oye, S O Lie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4479715     DOI： 10.1111/j.1600-0773.1974.tb00758.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN： 0001-6683


× No keyword cloud information.
  8 in total

1.  Clinical and pharmacologic studies with adriamycin-DNA complex in children with malignant disease.

Authors:  S O Lie; K K Lie; A Glomstein
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia.

Authors:  C Paul; M Björkholm; I Christenson; L Engstedt; G Gahrton; R Hast; G Holm; A Killander; B Lantz; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Peterson; B Simonsson; A M Stalfelt; A M Udén; B Wadman; G Oberg
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Treatment of acute nonlymphoblastic leukemia in adults with daunorubicin-DNA complex: a preliminary report.

Authors:  G Gahrton; M Björkholm; G Brenning; I Christenson; L Engstedt; S Franzén; B Gullbring; G Holm; C Högman; P Hörnsten; S Jameson; A Killander; C Simonsson-Lindemalm; D Lockner; B Lönnqvist; H Mellstedt; J Palmblad; C Paul; C Pauli; C Peterson; P Reizenstein; B Simonsson; K O Skårberg; A M Udén; B Wadman
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

4.  Uptake and distribution of daunorubicin and daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography.

Authors:  B Andersson; M Beran; B Eberhardsson; S Eksborg; P Slanina
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

5.  Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Authors:  A Trouet; D Deprez-De Campeneere
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

6.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.

Authors:  A Ferrant; R Hulhoven; A Bosly; G Cornu; J L Michaux; G Sokal
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

8.  Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex.

Authors:  B Andersson; M Beran
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.